Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Berghoff, AS; Mair, MJ; Spiró, Z; Abdel, Malak, C; El-Heliebi, A; Eckert, F; Furtner, J; König, F; Leibetseder, A; Nowosielski, M; Oberndorfer, S; Prietl, B; Pichler, J; Pieber, TR; Spiegl-Kreinecker, S; Urbanic, Purkart, T; Wöhrer, A; Widhalm, G; Preusser, M, , ATTRACT, study, group, .
Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT).
Neurooncol Adv. 2025; 7(1):vdaf056
Doi: 10.1093/noajnl/vdaf056
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- El-Heliebi Amin
- Pieber Thomas
- Prietl Barbara
- Urbanic Purkart Tadeja
- Study Group Mitglieder der Med Uni Graz:
- Enzinger Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Novel approaches to guide personalized treatment in glioblastoma are urgently needed. Given the poor predictive value of genetic biomarkers in glioblastoma, we are conducting a prospective clinical trial to investigate the novel approach of cultivated patient-derived tumor cells (PDCs) for ex vivo drug screening. METHODS: In this randomized phase 2 study, we are testing the ability of PDC-based ex vivo drug screening to formulate a personalized recommendation for maintenance treatment in patients with newly diagnosed glioblastoma with unmethylated MGMT promoter after combined radio-chemotherapy. Based on overall survival as the primary endpoint, we plan to include 240 patients (120 per group) to show with a power of 80% that we can increase the median survival from 12 to 17 months (hazard ratio 0.7). Patients will be randomized 1:1 to either the standard group (no drug screening) or the intervention group (drug screening and personalized recommendation for maintenance treatment). In the intervention group, automated drug screening will be performed on PDCs with 28 drugs used for the treatment of solid tumors and hematological malignancies. Based on the cytotoxic activity of these drugs, as quantified by relative viability based on adenosine triphosphate levels, a molecular tumor board will recommend a personalized treatment regimen. RESULTS: The first patient was enrolled in July 2024. Interim analysis of the ATTRACT study (NCT06512311) is expected in late 2027, and final results in 2030. TRIAL REGISTRATION: The ATTRACT trial is registered under the ID NCT06512311 (https://clinicaltrials.gov/study/NCT06512311).
- Find related publications in this database (Keywords)
- ATTRACT
- drug screening
- glioblastoma
- patient-derived tumor cells
- personalized medicine